Applied Therapeutics Inc (APLT) USD0.0001

Sell:$0.40Buy:$0.42$0.01 (2.44%)

Prices delayed by at least 15 minutes
Sell:$0.40
Buy:$0.42
Change:$0.01 (2.44%)
Prices delayed by at least 15 minutes
Sell:$0.40
Buy:$0.42
Change:$0.01 (2.44%)
Prices delayed by at least 15 minutes

Company Information

About this company

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).

Key people

John H. Johnson
Executive Chairman of the Board
Leslie D. Funtleyder
Chief Financial Officer and Principal Financial Officer, Director
Constantine Chinoporos
Chief Operating Officer and Chief Business Officer
Catherine Thorpe
Chief Accounting Officer
Dale Hooks
Chief Commercial Officer
Riccardo Perfetti
Chief Medical Officer
Teena L. Lerner
Lead Independent Director
Stacy J. Kanter
Independent Director
Jay S. Skyler
Independent Director
Click to see more

Key facts

  • EPIC
    APLT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US03828A1016
  • Market cap
    $59.46m
  • Employees
    35
  • Shares in issue
    141.58m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.